What is the main purpose of this 10-Q filing?

The Form 10-Q is a quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a company with a continuing disclosure requirement in the United States. It offers an update on the company's financial performance and financial position between annual reports.

What kind of financial information is typically found in a 10-Q filing for a company like Gilead?

A 10-Q typically includes unaudited financial statements (balance sheets, income statements, cash flow statements), management's discussion and analysis of financial condition and results of operations, legal proceedings, and other relevant disclosures regarding the company's business.

Given the date of this filing (1999), what might have been the key focus areas for Gilead Sciences at that time?

In 1999, Gilead Sciences was a relatively young company focused on developing antiviral therapies. Key focus areas would likely have included the progress of its pipeline drugs, particularly in areas like HIV/AIDS and hepatitis C, potential partnerships or licensing agreements, and securing funding for ongoing research and clinical trials.

Where can I find the actual financial details from this filing?

The provided text is a directory listing from the SEC's EDGAR database and does not contain the detailed financial statements or narrative analysis. To access the full report and its financial details, you would need to retrieve the actual .txt or HTML files associated with this filing from the SEC's EDGAR database.

GILD 10-Q Quarterly Report Q1 FY1999 — Revenue, Net Income, EPS

Summary

Gilead Sciences, Inc. filed its Form 10-Q for the quarterly period ended March 30, 1999. This filing provides a snapshot of the company's financial position and performance during this period. As a biopharmaceutical company, investors would be keenly interested in its progress on research and development, pipeline advancements, and any regulatory milestones. The limited information available in the provided directory listing makes a detailed financial analysis impossible, but it confirms the company is actively reporting to the SEC, indicating ongoing operations and regulatory compliance.

Key Highlights

1Gilead Sciences, Inc. (GILD) filed its quarterly report (10-Q) for the period ending March 30, 1999, on May 13, 1999.
2The filing indicates active operations and financial reporting by the company.
3This report falls within the historical context of the late 1990s, a critical period for many biotechnology firms.
4Investors would typically look for revenue figures, R&D expenses, net income/loss, and cash flow from this filing.
5Specific details on product sales, clinical trial progress, and regulatory approvals are usually key points of interest for Gilead's investors.
6The absence of specific financial data in the provided text necessitates a review of the full filing for a comprehensive understanding.

GILEAD SCIENCES, INC. Quarterly Report for Q1 Ended Mar 31, 1999

Summary

Key Highlights

Frequently Asked Questions